- Home
- FEBO vs KPRX Comparison
FEBO vs KPRX Comparison
Compare FEBO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- KPRX
- Stock Information
- Founded
- FEBO 1993
- KPRX 1998
- Country
- FEBO Hong Kong
- KPRX United States
- Employees
- FEBO N/A
- KPRX N/A
- Industry
- FEBO
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FEBO
- KPRX Health Care
- Exchange
- FEBO Nasdaq
- KPRX Nasdaq
- Market Cap
- FEBO 8.3M
- KPRX 9.2M
- IPO Year
- FEBO 2023
- KPRX N/A
- Fundamental
- Price
- FEBO $0.71
- KPRX $2.34
- Analyst Decision
- FEBO
- KPRX Strong Buy
- Analyst Count
- FEBO 0
- KPRX 1
- Target Price
- FEBO N/A
- KPRX $10.00
- AVG Volume (30 Days)
- FEBO 16.5K
- KPRX 47.9K
- Earning Date
- FEBO 11-25-2025
- KPRX 11-07-2025
- Dividend Yield
- FEBO N/A
- KPRX N/A
- EPS Growth
- FEBO N/A
- KPRX N/A
- EPS
- FEBO N/A
- KPRX N/A
- Revenue
- FEBO $17,110,653.00
- KPRX N/A
- Revenue This Year
- FEBO N/A
- KPRX N/A
- Revenue Next Year
- FEBO N/A
- KPRX N/A
- P/E Ratio
- FEBO N/A
- KPRX N/A
- Revenue Growth
- FEBO 11.58
- KPRX N/A
- 52 Week Low
- FEBO $0.61
- KPRX $2.21
- 52 Week High
- FEBO $3.34
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- FEBO 45.29
- KPRX 39.40
- Support Level
- FEBO $0.69
- KPRX $2.26
- Resistance Level
- FEBO $0.85
- KPRX $2.39
- Average True Range (ATR)
- FEBO 0.06
- KPRX 0.15
- MACD
- FEBO -0.01
- KPRX -0.01
- Stochastic Oscillator
- FEBO 10.37
- KPRX 18.48
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.